Table 1 Baseline characteristics of the patients included in the analyses
Tocilizumab plus methotrexate | Tocilizumab | Methotrexate | ||||
|---|---|---|---|---|---|---|
sDFR (n = 14) | Controls (n = 5) | sDFR (n = 13) | Controls (n = 11) | sDFR (n = 10) | Controls (n = 7) | |
Female gender, n (%) | 6 (43) | 4 (80) | 9 (69) | 8 (73) | 8 (80) | 6 (86) |
Age (years) | 53 (16) | 64 (10) | 58 (14) | 51 (13) | 50 (14) | 46 (17) |
BMI (kg/m2) | 25 (4) | 27 (4) | 25 (2) | 25 (5) | 29 (4) | 26 (3) |
Caucasian, n (%) | 13 (93) | 4 (80) | 13 (100) | 10 (91) | 10 (100) | 7 (100) |
Current smokers, n (%) | 3 (21) | 1 (20) | 2 (15) | 3 (27) | 1 (10) | 1 (14) |
Symptom duration (days), median (IQR) | 22 (21–40) | 19 (14–55) | 24 (18–39) | 21 (16–25) | 30 (13–40) | 31 (20–45) |
RF positive, n (%) | 5 (34) | 3 (60) | 8 (62) | 6 (55) | 9 (90) | 5 (71) |
Anti-CCP positive, n (%) | 5 (34) | 3 (60) | 8 (62) | 7 (64) | 7 (70) | 6 (86) |
CRP (mg/L), median (IQR) | 5 (2–13) | 5 (4–9) | 15 (4–27) | 14 (4–30) | 11 (5–18) | 5 (4–12) |
ESR (mm/h), median (IQR) | 18 (12–39) | 25 (23–29) | 26 (14–28) | 20 (9–39) | 25 (13–47) | 16 (13–25) |
DAS28 (range 0–9.4, 9.4 = maximum) | 4.7 (1.2) | 5.1 (0.9) | 5.0 (1.1) | 5.3 (1.3) | 4.6 (1.2) | 4.8 (0.9) |
HAQ (range 0–3, 3 = worst function) | 0.8 (0.5) | 1.5 (0.9) | 1.0 (0.6) | 1.4 (0.7) | 0.9 (0.6) | 1.0 (0.5) |
Sharp/van der Heijde score, median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–3) | 0 (0–2) | 0 (0–1) | 0 (0–0) |